Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm that can occur after subarachnoid hemorrhage, helping to maintain adequate blood flow to the brain in affected patients. By selectively antagonizing L‑type calcium channels in cerebral arteries, nimodipine reduces calcium influx and relaxes vascular smooth muscle, thereby mitigating the risk of vessel narrowing.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nimotop acts on the cerebral vascular system to prevent complications after subarachnoid hemorrhage.

- Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence and severity of vessel narrowing. - Delayed ischemic neurological deficits after SAH: helps maintain cerebral perfusion and limits neurological decline. - Neuroprotection in acute brain injury: provides calcium‑channel mediated protection of neuronal tissue.

Nimotop may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Cardiac arrhythmias: irregular heart rhythm. - Allergic reactions: rash, itching, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

Before using Nimotop, consider the following safety measures.

- Blood pressure monitoring: assess baseline and periodic readings. - Cardiac assessment: evaluate for existing arrhythmias or heart disease. - Liver function: check hepatic enzymes prior to initiation. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Store below 25°C: keep in the original container, protect from light and moisture.

Nimotop can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels. - Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Beta‑blockers: additive effects on heart rate and blood pressure. - Diuretics: monitor electrolytes and volume status.